XERS — Xeris Biopharma Holdings, Inc. stock price, charts and financials

Latest market price

7.94

+0.01+0.13%

Overview Short InterestFilings

XERSQT72Xeris Biopharma Holdings, Inc.·NASDAQ

Overview Short InterestFilings

7.94+0.13%

Loading chart...

Signal & projected range

Insider selling clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.52%$15.45 MESO+4.71%$16.69 ZBIO-0.93%$32.13 GHRS-1.77%$29.73 TSHA-1.59%$6.46 STOK-1.28%$32.29 ABCL+38.89%$9.63 VRDN-3.05%$22.87

Snapshot

Index	-	P/E	-	EPS (ttm)	0.07	Insider Own	11.66%	Shs Outstand	172.64M	Perf Week	-1.86%

Market Cap	1.37B	Forward P/E	21.81	EPS next Y	0.36	Insider Trans	-1.63%	Shs Float	164.66M	Perf Month	-8.00%

Enterprise Value	1.54B	PEG	0.01	EPS next Q	-	Inst Own	-	Short Float	6.12%	Perf Quarter	19.61%

Income	-17.11M	P/S	4.08	EPS this Y	107.34%	Inst Trans	-	Short Ratio	5.42	Perf Half Y	14.76%

Sales	335.42M	P/B	-	EPS next Y	150.50%	ROA	-4.17%	Short Interest	10.08M	Perf YTD	1.02%

Book/sh	-	P/C	20.62	EPS next 5Y	66.86%	ROE	-426.33%	52W High	10.09 -21.33%	Perf Year	44.44%

Cash/sh	-	P/FCF	21.09	EPS past 3/5Y	-	ROIC	12.51%	52W Low	5.26 51.05%	Perf 3Y	207.36%

Dividend Est.	-	EV/EBITDA	93.63	Sales past 3/5Y	38.46% 70.95%	Gross Margin	83.34%	Volatility	4.66% 3.99%	Perf 5Y	158.31%

Dividend TTM	-	EV/Sales	4.58	EPS Y/Y TTM	118.92%	Oper. Margin	10.91%	ATR (14)	0.38	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.02	Sales Y/Y TTM	55.17%	Profit Margin	-5.12%	RSI (14)	47.75	Recom	2.10

Dividend Gr. 3/5Y	-	Current Ratio	1.45	EPS Q/Q	116.67%	SMA20	-4.56%	Beta	0.73	Target Price	8.82

Payout	0.00%	Debt/Eq	-	Sales Q/Q	38.33%	SMA50	4.01%	Rel Volume	1.20	Prev Close	7.93

Employees	435	LT Debt/Eq	2.29	Earnings	Nov 05	SMA200	12.40%	Avg Volume	1.88M	Price	7.94

IPO Date	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	464.56% 3.28%	Net Debt/EBITDA	10.22	Volume	2,251,217	Change	0.13%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Dec-08-25	Initiated	Barclays	Overweight	$9.00
Oct-29-25	Reiterated	Oppenheimer	Outperform	$5.00 → $18
Mar-07-25	Reiterated	Piper Sandler	Neutral	$3.00 → $4.00
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Nov-11-24	Reiterated	HC Wainwright & Co.	Buy	$6.60
Oct-23-24	Reiterated	Oppenheimer		$5.00
May-10-24	Reiterated	Piper Sandler	Overweight	$3.00
Apr-28-22	Reiterated	Craig-Hallum	Buy	$6.50

Latest News

Aug-07-26

Aug-07-2604:04PM

Xeris Biopharma Q2 Earnings Call Highlightsmarketbeat.com

Aug-06-26

Aug-06-2603:04PM

Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcriptseekingalpha.com

10:31AM

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metricszacks.com

07:00AM

Xeris Biopharma Reports Second Quarter 2026 Financial Resultsbusinesswire.com

Jul-23-26

Jul-23-2608:00AM

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026gurufocus.com

Jul-08-26

Jul-08-2611:40AM

Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?zacks.com

Jul-02-26

Jul-02-2611:00PM

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)gurufocus.com

04:05PM

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)businesswire.com

Jun-30-26

Jun-30-2607:00AM

Xeris Announces Updates to Its Board of Directorsbusinesswire.com

Jun-11-26

Jun-11-2604:40PM

Xeris Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Regarding Its Patent Application Entitled Compositions And Methods Of UseBenzinga

07:09AM

Xeris Biopharma Enters Separate Exchange Agreements With Certain Holders Of Its 8.00% Convertible Senior Notes Due 2028 To Retire ~$23M Of The Notes For ~$23M In Cash And A Number Of SharesBenzinga

Company

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	335	292	203	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	56	53	37	—	—	—	—	—	—
Gross Profit	280	238	166	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	208	182	163	—	—	—	—	—	—
Research and Development	35	31	26	—	—	—	—	—	—
Other Operating Expense	0	1	11	—	—	—	—	—	—
Operating Income	37	25	-34	—	—	—	—	—	—
Interest Expense	28	29	33	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-26	5	10	—	—	—	—	—	—
Net Income Before Taxes	-17	1	-57	—	—	—	—	—	—
Income Taxes	0	0	-2	—	—	—	—	—	—
Consolidated Net Income	-17	1	-55	—	—	—	—	—	—
Net Income From Continuing Operations	-17	1	-55	—	—	—	—	—	—
Net Income	-17	1	-55	—	—	—	—	—	—
EPS (Recurring)	-0.10	0.00	-0.37	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.10	0.00	-0.37	—	—	—	—	—	—
EPS (Diluted)	-0.10	0.00	-0.37	—	—	—	—	—	—
EBITDA	16	13	-14	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	2,453.12	—	—	—	—	—	—	—
Price To Sales Ratio	4.10	4.30	2.45	—	—	—	—	—	—
Gross Margin	83.58	81.51	81.77	—	—	—	—	—	—
Operating Margin	11.04	8.56	-16.75	—	—	—	—	—	—
Net Margin	-5.07	0.34	-27.09	—	—	—	—	—	—
Shares Outstanding	173	160	147	—	—	—	—	—	—
Market Capitalization	1,374	1,256	498	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McCulloch Kevin	See Remarks	Aug 03 '26	Sale	8.02	15,000	120,240	1,676,126	Aug 04
Hecht Beth	See Remarks	Aug 03 '26	Sale	8.01	16,666	133,553	1,144,462	Aug 04
Pieper Steven	See Remarks	Jul 07 '26	Sale	8.52	27,600	235,276	1,366,053	Jul 07
Pieper Steven	See Remarks	Jul 06 '26	Sale	8.50	17,400	147,900	1,393,653	Jul 07
McCulloch Kevin	See Remarks	Jul 01 '26	Sale	8.03	90,000	722,511	1,691,126	Jul 02
Hecht Beth	See Remarks	Jul 01 '26	Sale	8.03	16,666	133,860	1,161,128	Jul 02
BORMANN-KENNEDY BARBARA-JEAN ANNE	Director	Jun 04 '26	Sale	6.09	16,000	97,507	126,500	Jun 05
HALKUFF DAWN	Director	Jun 04 '26	Sale	6.09	20,000	121,886	95,000	Jun 05
JOHNSON JOHN	Director	Jun 04 '26	Sale	6.09	15,000	91,422	683,083	Jun 05
PERSKY MARLA	Director	Jun 03 '26	Sale	5.90	15,500	91,433	126,500	Jun 05
Hecht Beth	See Remarks	Jun 01 '26	Sale	6.06	16,667	100,982	1,176,506	Jun 02
Hecht Beth	See Remarks	May 01 '26	Sale	6.23	16,667	103,805	1,193,173	May 01
Hecht Beth	See Remarks	Apr 01 '26	Sale	5.99	16,667	99,859	1,209,840	Apr 03
Brady James Aloysius	Director	Mar 30 '26	Sale	5.54	10,834	60,036	89,166	Apr 01
McCulloch Kevin	See Remarks	Mar 12 '26	Option Exercise	4.09	48,898	199,992	1,777,725	Mar 16

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.